BioStock: PHIs CEO eyes new business opportunities

March 31, 2022
Language flag

In 2021, PHI entered into a partnership with the US-based RegenMed Development Organization with the goal of establishing the company’s HoloMonitor technology as the standard quality control equipment in the growing field of regenerative medicine. The company has also chartered a new course when it comes to marketing strategy, with a sharp increase in sales over the last 4 quarters as a result. BioStock contacted CEO Peter Egelberg to find out more about the rights issue of just over 72 million SEK that is currently underway, and his vision for the future.

Read the full interview with Peter Egelberg on biostock.se.

Latest News

Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ) 14 March 2024

On Thursday, March 14, 2024, Phase Holographic Imaging PHI AB (publ), held an extraordinary general meeting. The following resolutions were passed at the meeting.
blue-cells_white-bg_banner

Shaping the future of Regenerative Medicine – PHI’s vision for QPI in Cell Therapy Manufacturing

PHI presents a comprehensive opinion piece detailing the versatility and potential the Company sees for Quantitative Phase Imaging (QPI) technology in Regenerative Medicine. PHI outlines how QPI will offer enhanced cell quality control in the cell manufacturing process, thereby addressing a central puzzle piece for making cell-based therapies safe, affordable, and accessible for all.
Altium_logo

New Distributor Partner Manager at Altium set to enhance global sales for PHI

PHI is conveying the news that its global distributor, Altium ., has appointed a PHI-dedicated distributor partner manager. This strategic step is set to significantly enhance the reach and sales performance of PHI’s HoloMonitor technology on a global scale.
See All News